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Abstract: 
We recently showed an association between the FCGR3A V/F polymorphism and the biological response 
[assessed on the basis of a C-reactive protein (CRP) concentration decrease] to infliximab in Crohn's disease. 
The CRP and FCGR3A genes are located on the same 1 q23 locus. The present study aimed: (i) to exclude a 
linkage disequilibrium (LD) between the two genes and (ii) to study the association between CRP 
polymorphisms and the response to infliximab, particularly the decrease in CRP after treatment, in Crohn's 
disease patients. FCGR3A (V/F) polymorphism and three CRP polymorphisms (-717G/A, 1444C/T, CRP 4A/G) 
were determined in 206 healthy blood donors and 189 Crohn's disease patients who had received infliximab for 
either refractory luminal or fistulizing Crohn's disease. Clinical response was defined as complete, partial or 
absent according to the same definition as in controlled trials. The biological response was defined on the basis 
of CRP decrease. There was no LD between CRP and FCGR3A in healthy donors or Crohn's disease patients. 
CRP polymorphisms had no impact on CRP decrease after infliximab. The proportions of Crohn's disease having 
a positive clinical or biological response were not statistically different among the various genotypes of CRP 
polymorphisms. There was no LD between CRP and FCGR3A polymorphisms. CRP polymorphisms were not 
associated with the response to infliximab in Crohn's disease.  
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INTRODUCTION 
Infliximab is a monoclonal chimeric antibody [immunoglobulin (Ig)Gl] directed against tumour necrosis factor 
(TNF)-α [1] and has been used as a treatment for Crohn's disease for several years. Although it is effective in 
refractory and fistulizing forms of the disease [2,3], there is an inter-individual variability in response to this 
drug, associated with several clinical or biological factors [4-7]. Particularly, a positive clinical response to 
infliximab has been associated with an elevated C-reactive protein (CRP) level before treatment [8]. 
Furthermore, a polymorphism in the FCGR3A gene, encoding a receptor for the Fc portion of IgGs, as involved 
in antibody-dependent cell-mediated cytotoxicity (ADCC), was shown to be associated with the biological 
response to infliximab in patients with Crohn's disease: FCGR3A-158V/V patients had a better response, as 
assessed by variation in CRP concentrations before and after treatment, compared to F carriers [9]. CRP, a 
member of the pentraxin family, is a plasma protein that contributed to innate host defence. It is also an acute 
phase protein that is usually elevated in active Crohn's disease. The gene coding for CRP has been mapped to 
lq23, approximately 2000 kb downstream of FCGR3A in the centromeric position of the FCGR gene cluster. 
Due to this close physical location, a genetic linkage disequilibrium (LD) between these two genes is possible 
[10], and might explain the better decline in CRP concentrations in FCGR3A-158V homozygous patients. If this 
was the case, the CRP gene would not necessarily have a direct impact on the objective response to infliximab, 
but rather could influence the magnitude of the CRP decrease in the serum after infliximab treatment. 
Indeed, several functional polymorphisms have been described in the CRP gene, such as the -717G/A 
substitution located in the promoter or the 1444C/T variant in the 3' untranslated region (UTR). The -717G/A 
substitution was not associated with variations in CRP concentrations [11] but -717G/G homozygotes had a 
greater risk of developing type 2 diabetes in Pima Indians [12]. The 1444C/T substitution located in the 3' UTR 
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was associated with variations in CRP serum concentrations: CRP concentrations were higher in 1444T/T 
homozygous healthy volunteers both at baseline and after exercise than in 1444C carriers [11]. In patients 
undergoing coronary artery bypass, mean CRP concentrations after surgery were also higher in 1444T/T 
homozygotes [12]. More recently, in a cohort of patients suffering from systemic lupus erythematosus (SLE) and 
their family members, it was also found that the CRP haplotype containing the 1444T allele was associated with 
high basal CRP concentrations. In the same study, a new polymorphism named CRP 4, also located in the 3' 
UTR, was identified and linked with SLE; the CRP 4A rare allele was associated with low basal CRP 
concentrations, with a gene dose effect [13]. 
The present study aimed: (i) to analyse LD between CRP -717G/A, CRP 1444C/T, CRP 4A/G and FCGR3A 
4985 G/T (encoding the 158V/F amino acid variants in the protein, respectively) polymorphisms and (ii) to 
evaluate the association between CRP gene polymorphisms and response to infliximab, particularly the decrease 
in CRP. 
PATIENTS AND METHODS 
Study population 
Blood samples were obtained from two hundred and six healthy anonymous blood donors from Tours (France) 
for LD analysis. The second part of our study was based on a cohort of 189 patients with Crohn's disease, largely 
similar to the one used in a previous study [9]. Briefly, all patients were treated with infliximab for the first time. 
They had refractory luminal or fistulizing Crohn's disease. Approval from the Ethics Committee of Liège 
University was obtained and patients provided their written informed consent for both infliximab treatment and 
pharmacogenetic ancillary studies. The demographic and clinical characteristics of the patients are given in 
Table 1. There were two subgroups of patients: 137 patients with active luminal (non-fistulizing) disease and 52 
patients with fistulizing disease. Luminal Crohn's disease patients were treated with a single infusion of 
infliximab (5 mg/ kg). Crohn's disease activity index (CDAI) [14] was calculated and CRP measured (by routine 
procedure using immunoturbidimetry, in local laboratories, CRP values then being normalized according to the 
upper limit of the normal value in each laboratory) at weeks 0 and 4. Patients with fistulizing disease were 
treated with three consecutive infusions (5 mg/kg) at weeks 0, 2 and 6. CDAI was calculated, CRP measured and 
fistulous tracks examined, at weeks 0 and 10. 
 
Table 1: Demographic, clinical and biological characteristics of the Crohn's disease patients (n = 189) 
Characteristic Value 
Mean ± SD Crohn's diseases activity index 263.5±121.7 
Median C-reactive protein (ιnormalize id) (range) 6.7 (1-80) 
Female/male (%) 116/73 (61.4/38.6) 
Fistulizing/refractory (%) 52/137 (27.5/72.5) 
Median age (years) (range) 34 (1 6-76) 
Disease location  
    Ileal (%) 36 (19.0) 
    Colonic (%) 63 (33.3) 
    lleocolonic (%) 77 (40.7) 
    Upper gastrointestinal involvement (%) 13 (6.9) 
    Anal involvement (%) 74 (39.1) 
Concomitant treatment  
    5-aminosalicylates (%) 88 (46.7) 
    Corticosteroids (%) 80 (42.3) 
    Immunosuppressives (%) 1 20 (63.5) 
    Smoking (%) 66 (34.9) 
 
Classification of response to infliximab 
The response to infliximab was assessed on the basis of both clinical and biological evolution. Clinically, 
patients were classified as complete responders, partial responders or non-responders according to published 
controlled clinical trials [2,3]. In non-fistulizing disease, patients were considered complete or partial responders 
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at week 4, if they had a decrease of CDAI below 150 or a decrease of at least 70 points from baseline, 
respectively. In fistulizing disease, patients were considered as complete or partial responders at week 10, in the 
case of complete fistula closure or a decrease of at least 50% in fistula drainage at two consecutive visits. 
Furthermore, the variation in CDAI between pre-treatment (week 0) and post-treatment periods (week 4 or 10) 
was calculated for all patients. 
Biologically, patients were classified as complete, partial or non-responders at 4 weeks (non-fistulizing disease) 
or 10 weeks (fistulizing disease) on the basis of CRP variation. This analysis was performed on a subgroup of 
148 patients for whom CRP values before and after treatment were available and who had an elevated CRP 
(more than twice the upper limit of the normal range) before treatment. Patients were classified as complete 
responders or partial responders in the case of normalization of CRP after treatment or a decrease of at least 25% 
from baseline level, respectively. Furthermore, for all patients, the variation of CRP (in absolute and relative 
value) was calculated between pre-treatment (week 0) and post-treatment periods (week 4 or 10). 
DNA analysis 
For healthy blood donors, genomic DNA was extracted from 2 ml of EDTA-anticoagulated blood with the 
Qiamp DNA Blood Midi Kit (Qiagen, Courtaboeuf, France) according to the manufacturer's recommendations. 
DNA concentrations were determined at 260 nm and samples were stored at -20°C until use. For Crohn's 
patients, genomic DNA was isolated until use as previously described [9] and stored at -20°C. 
FCGR3A-158V/F and CRP 4A/G genotyping were performed according to previously described allele specific 
polymerase chain reaction (PCR) [15] and PCR-restric-tion fragment length polymorphism (RFLP) [13] 
methods, respectively. 
For the CRP 1444C/T polymorphism, a new PCR-RFLP analysis assay was set up using a reverse primer 
originally described by Brull et αl. [11], but with slight modifications including a newly designed forward primer 
(Table 2). The reverse primer covers nucleotides 1579-1600 of the Genbank M11880 sequence and the forward 
primer covers nucleotides 1419-1443. The forward primer contains one mismatch (underlined) which creates a 
1444T allele-specific restriction site for NlaIII (6ATG), and is 5'-elongated (italic) to obtain a 30-bp difference 
between the two PCR products. The 20 µl PCR reaction mixture contained 50 ng genomic DNA, 2mM MgCl2, 
200 µM of each dNTP (MBI Fermentas, Mundolsheim, France), 1 µM of each primer and 0.5 U of EurobioTaq 
DNA polymerase (Eurobio, Les Ulis, France) in its specific buffer. Samples underwent 40 PCR cycles (60 s at 
94°C, 60 s at 61.2°C and 60s at 72°C) using an iCycler thermocycler (Biorad, Marnes la coquette, France). After 
digestion of PCR products with NlaIII, an electrophoresis in a 3% agarose gel discriminated the two alleles 
(Table 2). 
For the -717G/A CRP variant, known as SNP 133552 [12] or RS2794521 [11], PCR was conducted as described 
above except that the annealing temperature was 65°C and that the reaction mixture contained 1.5 mΜ MgCl2, 
with primers defined by Wolford et αl. [12]. PCR products were digested with NlαIII and the G allele was 
visualized as a fragment of 184 bp (five NlαIII restriction sites) and the A allele as a fragment of 163 bp (six 
NlαIII restriction sites) (Table 2). 
CRP 1444C/T-CRP 4A/G haplotypes, as well as CRP 1444C/T-CRP 4A/G-CRP -717G/A haplotypes, were 
constructed considering only non-ambiguous patients (i.e. those having no more than one heterozygosity for the 
three polymorphisms studied). 
Table 2    Primers and enzyme used in polymerase chain reaction-restriction fragment length polymorphism 
assays 
Polymorphism Primers Allele Size 
CRP -717 Forward: ATGCTCCTCCCAGAGCa G 184 
 Reverse: GCCGTCATTTAGTGCCAAGa A 163 
CRP +1444 Forward: ATATTAATAAGGAGCTCGTTAACTATGCTGGGACAb C 190 
 Reverse: TTCTCAGCTCTTGCCTTATGAG T 160 
CRP 4 Forward: CGAGTGAGACATCTTCTTG A 227 
 Reverse: CTTATAGACCTGGGCAGT G 130 
aDefined in Wolford et al. [1 2]. 
bUnderlined position indicates a mismatch introducing a restriction site on the T allele; italic characters indicate the unspecific 5' tail. 
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Statistical analysis 
An exact test [16] tested departure from Hardy-Weinberg equilibrium using GENEPOP software [17]. 
Significance of LD between two loci was estimated using a chi-square test between maximum likelihood 
estimated and expected (under independency hypothesis) haplotypes (EH software) [18]. LD values were 
calculated by subtracting estimated and expected haplotype frequencies. Subsequently, relative LD values were 
obtained by dividing LD by maximum LD (product of lower frequency allele frequencies). Allele and genotype 
proportions in the two different populations were compared using a chi-square test for independency and Fisher's 
exact test, respectively. In the subgroup of patients with active luminal disease (n = 137), baseline CRP values 
were compared in various subgroups of patients, who were defined according to CRP genotypes, using Mann-
Whitney and Kruskal-Wallis tests. Furthermore, the proportions of various CRP genotypes were compared 
between patients with elevated or normal baseline CRP using a chi-square test for independence. Proportions of 
patients having a positive clinical or biological response to infliximab in the different genotype groups were 
compared using a chi-square or Fisher's exact test, as required. The decreases in CRP or CDAI values according 
to genotype were compared using Kruskal-Wallis or Mann-Whitney tests, as required, P-values were corrected 
(Pc) for multiple tests (three gene polymorphisms tested for influence on baseline CRP values, as well as clinical 
and biological responses to infliximab). Pc < 0.05 was considered statistically significant. 
 
RESULTS 
CRP genotyping of normal individuals and infliximab-treated Crohn's disease patients 
To elucidate a possible role for FCGR3A-CRP LD in the previously described association between the biological 
response to infliximab in Crohn's disease patients and the FCGR3A-158V/F polymorphism, three relevant CRP 
polymorphisms were genotyped in our 189 patients and in 206 healthy individuals. All the genotype frequencies 
were in Hardy-Weinberg equilibrium in both healthy blood donors and Crohn's disease patients. There was no 
statistically significant difference in allele or genotype proportions between the two different populations. 
Particularly, frequencies of C/C, C/T and T/T CRP + 1444 genotypes were 40.8%, 48.5% and 10.7% versus 
41.2%, 48.7% and 10.1% in controls and Crohn's disease patients, respectively (P = 0.99); frequencies of A/A, 
A/G and G/G CRP -717 polymorphisms were 54.4%, 38.8% and 6.8% versus 56.3%, 37.1% and 6.6% in 
controls and Crohn's disease, respectively (P = 0.93); frequencies of A/A, A/G and G/G CRPA genotypes were 
10.7%, 42.2% and 47.1% versus 9.1%, 45.7% and 45.2% in controls and Crohn's disease patients, respectively 
(P = 0.75). As previously published [13], each studied CRP gene polymorphism was in LD with each other. This 
was observed both in healthy donors and in Crohn's disease patients (Fig. 1). By contrast, none of these three 
polymorphisms proved to be in LD with FCGR3A, neither in healthy donors nor in Crohn's disease patients (Fig. 
1). 
CRP 1444C/T and CRP 4A/G polymorphisms produced three main haplotypes: CA, CG and TG, representing 
29.3%, 39.1% and 30.1% of haplotypes in healthy controls (184 haplotypes in 92 subjects) and 28.3%, 41.8% 
and 29.3% in Crohn's disease patients (184 haplotypes in 92 patients), respectively. When adding the CRP -
717G/A polymorphism, four main haplotypes were produced: CAA, CGA, CGG and TGA representing 27.7%, 
21.2%, 17.9% and 29.3% of haplotypes in healthy controls (184 haplotypes in 92 subjects) and 27.7%, 23.4%, 
18.5% and 28.3% in Crohn's disease patients (184 haplotypes in 92 patients), respectively. 
CRP genotypes and baseline CRP concentrations in Crohn's disease patients 
Although Crohn's disease patients overall do not differ from a normal Caucasian population in the CRP allele or 
genotype frequencies, it is possible that CRP polymorphisms are associated with particular presentations of the 
disease, particularly CRP concentrations. The subgroup of Crohn's disease patients with active luminal disease 
and elevated CRP (more than the upper limit of the normal value) had CRP genotype proportions similar to those 
of Crohn's disease patients with active luminal Crohn's disease and normal CRP (data not shown). No significant 
differences were found either when looking at haplotype frequencies (data not shown). Furthermore, median 
baseline CRP was similar in the various genotypic groups (Table 3). 
CRP genotypes according to clinical and biological response to infliximab 
Mean CDAI before and after infliximab treatment was 263.5 ±121.7 and 151.9 ±119.5, respectively. Clinical 
response was complete in 97 patients (51.3%), partial in 34 (18%), absent in 44 (23.3%) and not assessable in 14 
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(7.4%). Median (normalized) CRP before and after infliximab was 6.7 (1-80) and 3.2 (1-52.3), respectively. 
Biological response (as previously defined [9]) was complete in 68 patients (45.9%), partial in 46 (31.1%) and 
absent in 34 (23%). Overall, there was a significant correlation between relative decrease in CDAI and relative 
decrease in CRP (r = 0.298, 95% confidence interval = 0.125-0.454; P = 0.0007). However, in a significant 
number of cases, there was a discrepancy between the clinical and biological response as previously defined 
(discordance in 34.1% of cases). 
There was no significant association between the studied CRP gene polymorphisms and the clinical or biological 
response to infliximab in Crohn's disease. Proportions of patients with a positive clinical or biological response 
to infliximab, as well as median relative decrease in CRP, are shown in Table 3. There was no significant 
difference in median absolute CRP decrease. There was no significant difference in CDAI decrease between 
CRP genotypes (data not shown). Finally, no significant difference was found when looking at haplotype 
frequencies (data not shown). 
Fig. 1: Linkage disequilibrium (LD) between the four studied loci in (a) healthy blood donors and (b) in Crohn's 
disease patients. The values of relative LD (= 1 when one of the four theoretical haplotypes is not represented) 
between each biallelic polymorphism are presented in boxes. Grey boxes, Significant LD (P<0.05); empty, non-




We have previously shown that a positive response to infliximab in Crohn's disease is associated with elevated 
CRP serum concentrations before treatment [8]. More recently, we also generated data indicating that the 158V/ 
F polymorphism of FCGR3A, a gene coding for an IgG Fc receptor potentially involved in ADCC, is associated 
with more prominent decrease in CRP concentrations in response to infliximab in Crohn's disease [9]. Some 
published data suggest that functional polymorphisms in CRP gene may influence serum CRP concentration in 
humans [11,13]. Finally, the CRP gene is located in lq23, close to the FCGR3A gene. Despite these complex 
relationships between CRP, FCGR3A polymorphism, Crohn's disease and the response to infliximab, the present 
study shows that there is no LD between the FCGR3A and CRP studied polymorphisms. Moreover, no 
association was observed between several CRP polymorphisms and CRP serum concentrations in active Crohn's 
disease before infliximab treatment on the one hand or clinical and biological response to infliximab on the 
other. 
Because the association that we have previously reported between the FCGR3A gene and response to infliximab 
in Crohn's disease was significant for the biological response (defined by the CRP decrease after treatment) but 
not for the clinical response [9], and because these two genes are located close to each other on lq23, this 
association could have been a false-positive association due to a LD between these two genes. The true 
association would then have been with one or several of the described CRP gene polymorphisms. Our data show 
that this is probably not the case because there is no LD between the CRP gene polymorphisms studied and the 
FCGR3A-158V/F polymorphism both in controls and in a population of Crohn's disease patients who were 
treated with infliximab and because no association was observed between CRP polymorphisms and the response 
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to infliximab, particularly the decrease in serum CRP after treatment. 
Similar to previously published studies [11,13], the three CRP polymorphisms studied were themselves in LD. 
This LD allowed Russell et al. [13] to define, in a large cohort of SLE families, five major haplotypes based on 
five genotypic polymorphisms. These haplotypes were associated with different baseline CRP concentrations. 
Two of these polymorphisms (CRP 1444 and CRP 4) were selected for use in the present study because they 
could define three major haplotypes groups among the five Russell's haplotypes, each of them being 
characterized with a particular pattern of basal CRP production: 1444C and CRP 4A alleles define Russell's 
haplotypes 2 and 5 associated with significantly low CRP basal concentration, 1444T and CRP 4 G alleles define 
haplotype 1 associated with high CRP concentration and 1444C and CRP 4 G alleles characterize haplotypes 3 
and 4 [13]. Moreover, we have included an analysis of the CRP -717G/A polymorphism, which was not included 
in the Russell's study but which has been associated with type 2 diabetes [12]. A haplotype analysis performed 
on our cohort of normal individuals demonstrates that CRP -717G/A polymorphism brings a further level of 
complexity to Russell's haplotypes. Indeed, when analysing the three precedently defined groups of haplotypes 
and the -717G/A polymorphism, we could define four major haplotypes. The first two groups containing 
haplotypes 1, 2 and 5 are mainly associated with the -717A allele but the third group is associated either with -
717A or G allele creating four major haplotypes in our analysis. The three CRP polymorphisms presently studied 
therefore ensure a correct assessment for the CRP gene. However, none of these three tag CRP polymorphisms 
was found to be in LD with FCGR3A, either individually or as haplotypes, leading to the conclusion that 
FCGR3A influences the biological response to infliximab by itself, probably by facilitating the killing of TNF-α-
expressing inflammatory cells in the gut [9]. The probability that another CRP polymorphism would be in LD 
with FCGR3A cannot be totally excluded but is extremely low. 
Whatever the risk of LD between FCGR3A and CRP, which can now be considered as very low, the possible 
association between CRP polymorphisms and the response to infliximab remains a relevant question. Indeed, a 
positive response to infliximab has been associated with an elevated CRP before treatment [8]. The paradoxical 
absence of a CRP increase in some patients with clinically active Crohn's disease may be due to a genetic 
predisposition to produce less CRP. Indeed, family studies have suggested that 30-40% of the variation in 
plasma CRP concentration is genetically determined [19]. The three variants of the CRP gene studied here have 
been shown to be functional, and either associated with certain diseases [12,13] or with variations in CRP plasma 
concentrations [11,13]. However, none of the CRP polymorphisms was found to be associated with low 
CRP concentrations before treatment. According to the genetic hypothesis, some CRP genotypes could also be 
associated with a suboptimal response to infliximab in Crohn's disease, particularly when assessed by CRP 
decrease. However, again, this is not the case in the present study because similar response rates were observed, 
according to both clinical and biological criteria, in the various genotype groups, whatever the CRP genotype 
considered. Thus, CRP polymorphisms do not appear to be the basis of the association between CRP 
concentration before treatment and the response to infliximab in Crohn's disease. Therefore, other explanations, 
including functional symptoms and particular pathways of inflammation, appear to provide more likely reasons 
for low CRP concentrations despite active Crohn's disease and suboptimal response to infliximab. The fact that 
CRP polymorphisms do not have any influence on CRP variations after infliximab treatment is also important 
because CRP variation is considered as a relevant marker of response to infliximab in addition to clinical scores 
such as CDAI [2,8,9]. 
The observation that CRP -717, CRP 1444 and CRP 4 had no influence on serum CRP concentrations before 
infliximab treatment appears to be in contrast to that observed in coronary disease or in SLE, where CRP 1444T 
allele and CRP 4A allele were associated with higher and lower CRP concentrations, respectively [11,13]. 
However, in a recent study of a cohort of patients with coronary heart disease and a population of controls, this 
association was not confirmed [20]. One of the main reasons for these discrepancies may be that CRP variants 
influence slight variations in low CRP levels in healthy individuals or diseases that are not associated with a 
significant elevation of CRP [20]. Furthermore, an association with higher levels of CRP in diseases such as 
Crohn's disease, which is associated with a pronounced elevation of this protein, would be very difficult to 
disclose, with the heterogeneity in the degree of inflammatory reaction being a major confounding factor. 
In conclusion, CRP -717, CRP 1444 and CRP 4 polymorphisms are not in LD with the FCGR3A-158V/F 
polymorphism previously associated with CRP decrease after infliximab treatment. In addition, these 
polymorphisms are not associated with the clinical or biological response to infliximab in Crohn's disease and, in 
particular, are not associated with CRP decrease after infliximab treatment. 
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Table 3    Baseline C-reactive protein (CRP), clinical and biological response to infliximab, according to CRP 
genotypes 
Locus Genotype Proportion of patients 
with 
positive clinical response 
to 
infliximab (%) 
Proportion of patients 
with 
positive 
biological response to 
infliximab (%) 
Median baseline CRP 
(normalized; median-
range) 
Median relative CRP 
decrease after 
infliximab (%) 
CRP -717G/A A/A 74/98 (75.5) 53/75 (70.7) 4.6 (1-80) -40 (-99-1461)a 
 A/G 43/60 (71.7) 50/58 (86.2) 6.1 (1-62.2) -66 (-98-100)a 
 G/G 9/1 2 (75) 4/8 (50) 5.6 (1-16.6) -14 (-73-571)a 
CRP 1444C/T T/T 1 6/1 9 (84.2) 8/12 (66.7) 5.2 (1-75) -32.5 (-97-39) 
 C/T 65/83 (78.3) 52/68 (76.5) 5.4 (1-67.2) -60 (-96-1461) 
 C/C 50/72 (69.4) 50/64 (78.1) 5.4 (1-80) -61 (-98-571) 
CRP 4A/G A/A 12/14 (85.7) 9/1 2 (75) 3.8 (1-63) -39 (-95-51) 
 A/G 57/81  (70.4) 53/70 (75.7) 5.2 (1-80) -62 (-91-1461) 
 G/G 59/76 (77.6) 50/64 (78.1) 5.8 (1-75) -56.5 (-98-571) 
aP=0.018; Po = 0.162 (Kruskal-Wallis). 
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